- G30 -

Home About Services Helpful Links Informacion en Espaol Contact Donate More Study of Oligorecurrent Prostate Cancer Finds Winning CombinationResearchers explore steam treatment for prostate cancerMyProstateScore version 2. 0 may help men avoid unnecessary biopsyAIassisted HIFU for Prostate CancerGovernor Hobbs proclaims September 2024 Arizona Prostate Cancer Awareness MonthRadioactive drugs strike cancer with precisionHRR Testing Underused in mCRPCPatient Selection for Radioligand TherapyPlantBased Diets Tied With Lower Prostate Cancer Progression Risk Better QOLBREAKING NEWS PCF Screening Guidelines for Black Men Now PublishedChange the Odds initiative to bridge the gap in cancer care disparitiesPCF Know your risk spread the wordUS Dept. of Defense Early screening is important for detection and treatment of prostate cancerSMYD3 enzyme role in prostate cancerHPV infections increase Prostate Cancer riskNew cancer treatment from inside the prostate glandPersonalized dosing improves patient outcomesFDA approves talazoparib plus enzalutamide for HRR genemutated mCRPCFDA approves new PSMA imaging agentImportant pending Prostate Cancer legislation that can affect you FDA approves New Jersey Pluvicto ProductionIsoPSA could eliminate need for biopsyNIH declines to force lower priceon XtandiLet39s support our sisters battling TripleNegative Breast CancerBRCA1 mutationNew Cancer Data Spark Outcry From Patient AdvocatesTargeting a single enzyme can kill prostate cancer cellsCedarsSinai Blood Test Detects and Profiles Prostate CancerAdvanced Prostate Cancer rates on the riseACS39s IMPACT initiative focuses on Prostate Cancer in Black menMetastasisDirected Therapy beneficial in Oligometastatic Prostate CancerResearchers identify new therapeutic approach against treatmentresistant prostate cancerNew genetic test for early detectionTest to Predict Prostate Cancer AgressivenessProstate Cancer MarkersHelp Individualize CareFDA approves lu177 treatment for men with advanced prostate cancerRadium223 w Enzalutamide could increase life expectancy in mCRPC The National Alliance of State Prostate Cancer Coalitions NASPCC recommends a baseline prostate specific antigen PSA blood test and digital rectal exam DRE beginning at age 40 at 35 if high risk including AfricanAmerica Men or men with a certain or indeterminate family history of prostate cancer and then periodically depending on those results. You should know and keep tract of all your PSA measurements and ANY CHANGE IN PSA should be discussed with your doctor.